Skip to main content

Biotech startup is creating genetically engineered ‘superblood’ to battle cancer

cgtoolbox / 123RF Stock Photo

Rubius Therapeutics, a biotech startup that is creating “superblood” to treat a range of conditions including cancer, has raised an extra $100 million to make its dream a reality. Previously, the company raised $120 million from investors, thereby bringing its total haul close to the one quarter of a billion dollars mark — all in less than one year.

Recommended Videos

Rubius is developing Red-Cell Therapeutics (RCT). These are genetically engineered, enucleated red cells which have been engineered to carry therapeutic proteins. Depending on the requirements, they can be loaded up with the necessary proteins to replace missing enzymes, kill tumors, and regulate the immune system for the battling of cancer and autoimmune diseases. They can then be transfused into patients to apply their healing powers.

Please enable Javascript to view this content

A couple of things make the technology neat. For one thing, the fact that the cells have no nucleus means that they are not recognized by the immune system. Red blood cells are also transported all over the body, which will allow the “superblood” to reach whichever tissue or organ it needs to reach. Between these two abilities, the idea is that Rubius is creating an off-the-shelf solution that wouldn’t need to be personalized to each patient.

The extra $100 million in funding will help speed up the development of these genetically engineered red blood cells so that they can reach us, the end user, more rapidly.

“The addition of this funding further strengthens our foundation and enables us to accelerate the development of our first wave of RCT products that are targeting treatment of enzyme deficiencies, cancer, and autoimmune disease,” Torben Straight Nissen, president of Rubius Therapeutics, said in a statement. “We have assembled an extremely talented team of investors, leadership and advisers, which all share the long-term vision of bringing novel cellular therapies to patients.”

Here at Digital Trends, we’ve previously covered projects such as micro-scale robots which could be used as drug delivery systems inside the human body. The idea of being able to help treat diseases — potentially ranging from cancer to diabetes — using targeted drug delivery is certainly an exciting one. It’s great to see that investors clearly think so, too!

Luke Dormehl
Former Digital Trends Contributor
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Hyundai Ioniq 5 sets world record for greatest altitude change
hyundai ioniq 5 world record altitude change mk02 detail kv

When the Guinness World Records (GWR) book was launched in 1955, the idea was to compile facts and figures that could finally settle often endless arguments in the U.K.’s many pubs.

It quickly evolved into a yearly compilation of world records, big and small, including last year's largest grilled cheese sandwich in the world.

Read more
Global EV sales expected to rise 30% in 2025, S&P Global says
ev sales up 30 percent 2025 byd sealion 7 1stbanner l

While trade wars, tariffs, and wavering subsidies are very much in the cards for the auto industry in 2025, global sales of electric vehicles (EVs) are still expected to rise substantially next year, according to S&P Global Mobility.

"2025 is shaping up to be ultra-challenging for the auto industry, as key regional demand factors limit demand potential and the new U.S. administration adds fresh uncertainty from day one," says Colin Couchman, executive director of global light vehicle forecasting for S&P Global Mobility.

Read more
Faraday Future could unveil lowest-priced EV yet at CES 2025
Faraday Future FF 91

Given existing tariffs and what’s in store from the Trump administration, you’d be forgiven for thinking the global race toward lower electric vehicle (EV) prices will not reach U.S. shores in 2025.

After all, Chinese manufacturers, who sell the least expensive EVs globally, have shelved plans to enter the U.S. market after 100% tariffs were imposed on China-made EVs in September.

Read more